Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections Public Deposited

http://ir.library.oregonstate.edu/concern/defaults/ws859k932

This is the publisher’s final pdf. The published article is copyrighted by American Society for Microbiology and can be found at:  http://aac.asm.org/.

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Enterococci are among the leading pathogens isolated in hospital-acquired infections. Current antimicrobial options for vancomycin- resistant enterococci (VRE) are limited. Prior data suggest that daptomycin at>6 mg/kg of body weight/day may be used to treat enterococcal infections. We retrospectively evaluated the effectiveness and safety of high-dose daptomycin (HD-daptomycin) therapy (>6 mg/kg) in a multicenter cohort of adult patients with enterococcal infections to describe the characteristics and outcomes. Two hundred forty-five patients were evaluated. Enterococcus faecium was identified in 175 (71%), followed by Enterococcus faecalis in 49 (20%) and Enterococcus spp. in 21 (9%); overall, 204 (83%) isolates were VRE. Enterococcal infections included bacteremia (173, 71%) and intra-abdominal (35, 14%) and bone and joint (25, 10%) infections. The median dosage and duration of HD-daptomycin were 8.2 mg/kg/day (interquartile range [IQR], 7.7 to 9.7) and 10 days (IQR, 6 to 15), respectively. The overall clinical success rate was 89% (193/218), and microbiological eradication was observed in 93% (177/191) of patients. The median time to clearance of blood cultures on HD-daptomycin was 3 days (IQR, 2 to 5). The 30-day all-cause mortality rate was 27%, and 5 (2%) patients developed daptomycin-nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients (3%) had creatine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated CPK and all patients were asymptomatic. Overall, there was a high frequency of clinical success and microbiological eradication in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and difficult-to-treat infections. No adverse event-related discontinuation of HD-daptomycin was noted. HD-daptomycin may be an option for the treatment of enterococcal infections.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Casapao, A. M., Sakoulas, G., Cosgrove, S. E., Rybak, M. J., Kullar, R., Davis, S. L., . . . Segreti, J. (2013). Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrobial Agents and Chemotherapy, 57(9), 4190-4196. doi:10.1128/AAC.00526-13
Academic Affiliation
Series
Keyword
Rights Statement
Funding Statement (additional comments about funding)
Publisher
Peer Reviewed
Language
Replaces

Relationships

Parents:

This work has no parents.

Last modified

Downloadable Content

Download PDF

Items